Passage Bio’s latest quarterly filing reveals a sharp reduction in workforce and heightened focus on strategic alternatives to enhance shareholder value. The company continues advancing its lead gene therapy programs targeting neurodegenerative diseases but faces substantial financial uncertainty with cash reserves dwindling. Its competitive moat is rooted in specialized gene therapies and partnerships, yet execution risks and capital constraints are critical challenges. Monitoring clinical trial progress, manufacturing scale-up, and strategic review outcomes will be key near-term milestones.